Omega-3 fatty acids (EPA + DHA) are the single most-studied supplement category for cardiovascular disease, inflammation, and brain function. The triglyceride form is more bioavailable than ethyl esters.
Omega-3 supplementation reduced fatal myocardial infarction risk by 8% (RR 0.92), with dose-response: higher doses produced larger effects.
EPA-dominant omega-3 (≥60% EPA) significantly reduced depression symptoms (SMD -0.99) vs placebo. DHA-only formulations were ineffective.
AHA scientific statement: 4 g/day EPA+DHA produces 20-30% reduction in serum triglycerides, comparable to fibrate medications.
Fish oil supplementation reduced joint pain intensity, morning stiffness, and NSAID consumption in inflammatory arthritis.
We prioritize randomised controlled trials and meta-analyses over single observational studies. Animal and in-vitro data are listed as "mechanistic", they suggest direction, not human effect size.
We don't cherry-pick favourable studies, omit conflicting evidence, or cite industry-funded trials without flagging the conflict of interest where known.
The research is one thing, what to take, at what dose, paired with what, is another. We compose stacks that turn the evidence into a daily routine.
Studies referenced are real published research. Summaries are paraphrased for accessibility, for exact methods and full text, click through to PubMed. Educational use only, not medical advice. Consult a qualified clinician before starting any new supplement.